GILD Stock Gilead Sciences, Inc.
US · NasdaqGSLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
HIV leadership, oncology optionality, and high shareholder returns create attractive defensive value.
Future value: $160.19 (+2.66%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Pipeline updates and income-oriented institutional demand.
- ▸Above 50-day MA (+4.84%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (90.4% of range) — strength
Is GILD a buy right now?
Trend: GILD is trading above the 50-day average (+6.32%), RSI 45 — neutral momentum, with a 3-month return of +18.14%.
Valuation & quality: Gilead Sciences, Inc. trades on forward P/E 15.9, PEG 2.31, price-to-book 16.65; fundamentals show net margin -10.6%, return on equity -20.7%, revenue growth 10.2% year on year.
Analyst consensus: 26 analysts have a mean 12-month price target of $160.19 (+0.9% vs the last close; range $126.00 – $185.00), consensus rating “buy”.
Income: trailing dividend yield 2.10%.
Our screen: STRONG BUY (score 4) — HIV leadership, oncology optionality, and high shareholder returns create attractive defensive value.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -6.40% | -6.10% | +2.70% | -6.00% | +3.10% | +12.40% | +1.90% | +6.50% |
Fundamentals
Analyst price target
Technical signals
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 17,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.